# Tirzepatide References — Full Citation List

> Full bibliography of Tirzepatide research sources cited across this site — Phase 3 trials, safety meta-analyses, pharmacovigilance studies, and the 2024–2025 clinical evidence. DOIs and PubMed URLs included.

## All citations used on this site

All references are drawn from peer-reviewed journals, regulatory documents in the corpus, and NCBI Bookshelf clinical-reference entries. See [Tirzepatide research](/research) for contextualised findings.

## References

[1] Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. https://pubmed.ncbi.nlm.nih.gov/30473097/
[2] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://pubmed.ncbi.nlm.nih.gov/32730231/
[3] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/
[4] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
[5] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[6] Safwan M, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obesity trials: a meta-analysis. Ann Saudi Med. 2025;45(2):129-137. https://pubmed.ncbi.nlm.nih.gov/40189856/
[7] Mishra R, et al. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review. Cureus. 2023;15(10):e46091. https://pubmed.ncbi.nlm.nih.gov/37908927/
[8] Shen P, et al. Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis. PLoS One. 2026. https://pubmed.ncbi.nlm.nih.gov/41894422/
[9] Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):323-334. https://pubmed.ncbi.nlm.nih.gov/38856224/
[10] Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. https://pubmed.ncbi.nlm.nih.gov/38912654/
[11] U.S. Food and Drug Administration. Tirzepatide injection prescribing information (FDA label, type 2 diabetes). FDA Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
[12] Farzam K, Patel P. Tirzepatide. StatPearls [Internet]. NCBI Bookshelf. 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/
[13] Campbell JE, et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss — chemistry, physiology, and clinical applications. Cell Metab. 2023;38(4):573-594. https://pubmed.ncbi.nlm.nih.gov/37591245/
[14] Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. https://pubmed.ncbi.nlm.nih.gov/37908750/
[15] Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Review. Drugs. 2026. https://pubmed.ncbi.nlm.nih.gov/41351656/
[16] Qazi S, et al. Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2026;14(7):850. https://pubmed.ncbi.nlm.nih.gov/41975852/
[17] Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. https://pubmed.ncbi.nlm.nih.gov/39555826/
[18] Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis. J Diabetes Investig. 2025;16(2):324-332. https://pubmed.ncbi.nlm.nih.gov/39569606/
[19] Almansour HA, et al. Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Database Reports. Healthcare (Basel). 2025;13(18):2259. https://pubmed.ncbi.nlm.nih.gov/41008391/
[20] Galli M, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis. J Am Coll Cardiol. 2025. https://pubmed.ncbi.nlm.nih.gov/40892610/
[21] Zhang Z, et al. Tirzepatide safety in type 2 diabetes: a disproportionality analysis of the FDA FAERS database. Endocr Connect. 2025. https://pubmed.ncbi.nlm.nih.gov/40631601/
[22] Nassar M, et al. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide use. Diabetes Metab Syndr. 2024;18(9):103116. https://pubmed.ncbi.nlm.nih.gov/39332263/
[23] Rasouli N, et al. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity. Diabetes Ther. 2025;16(3):685-698. https://pubmed.ncbi.nlm.nih.gov/40016573/
[24] Look M, et al. Body composition changes during weight reduction with tirzepatide in type 2 diabetes and obesity. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/
[25] Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition in Older Adults: A Systematic Review. Ann Intern Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41996180/
[26] Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(7):1178-1189. https://pubmed.ncbi.nlm.nih.gov/38687506/
[27] Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;109(12):3081-3091. https://pubmed.ncbi.nlm.nih.gov/39418085/
[28] Urva S, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. https://pubmed.ncbi.nlm.nih.gov/32519795/
[29] Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/
[30] Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus changes: a systematic review and meta-analysis. Obes Rev. 2025;26(5):e13929. https://pubmed.ncbi.nlm.nih.gov/40186344/
[31] Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal. JAMA Intern Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41284285/
[32] et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Dual Agonists: A Pharmacovigilance Review. Cureus. 2025;17(1):e92454. https://pubmed.ncbi.nlm.nih.gov/41111833/
[33] U.S. Food and Drug Administration. FDA approval for chronic weight management (tirzepatide) — press announcement. FDA News & Events. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
[34] Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. https://pubmed.ncbi.nlm.nih.gov/38912654/
[35] Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/41406444/
[36] Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/39536238/
[37] Galindo RJ, et al. Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. JAMA Netw Open. 2026;9(4):e2633274. https://pubmed.ncbi.nlm.nih.gov/41885866/
[38] Park J, et al. Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-analysis. Endocrinol Metab (Seoul). 2025. https://pubmed.ncbi.nlm.nih.gov/39814031/

---

A newsroom reading of the tirzepatide safety record — the 2024–2025 trials and meta-analyses set down and cited, with no clinic, no prescriber, and no verdict on any individual's risk.